Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

NCT: NCT06122610 · RECRUITING

NCT IDNCT06122610
StatusRECRUITING
Start Date2025-03-07
Completion2026-06

Brief Summary

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans

Frequently Asked Questions

What is Using Novel Imaging to More Safely Treat Neuroendocrine Tumors?

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors is a clinical trial registered under NCT06122610. Current status: RECRUITING.

What is the status of NCT06122610?

The current status of NCT06122610 (Using Novel Imaging to More Safely Treat Neuroendocrine Tumors) is: RECRUITING.

When did Using Novel Imaging to More Safely Treat Neuroendocrine Tumors start?

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors started on 2025-03-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑